Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Lexicon Pharma (LXRX) Tops Q3 EPS by $1.22, Revenues Beat
November 7, 2019 7:24 AM ESTLexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of $1.95, $1.22 better than the analyst estimate of $0.73. Revenue for the quarter came in at $294.45 million versus the consensus estimate of $64.25 million.
Third Quarter 2019 Financial Highlights
Revenues: Revenues for the three months ended September 30, 2019 increased to $294.4 million from $7.0 million for the corresponding period in 2018, primarily due to an increase of collaborative revenues of $260 million from the termination of the alliance with Sanofi and recognition of the remaining amount of $23.5 million allocated to performance obligations from the initial agreement with Sanofi and an increase in net... More